MTHFR

Across TCGA pan-cancer cohorts, MTHFR mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTHFR data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MTHFR mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MTHFR expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where MTHFR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	1.000	0.132	.010	46	view →
PDAC	OS	Quartile	All	0.623	0.292	.007	20	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	5	view →
LUAD	DFS	Quartile	All	1.000	0.795	.017	4	view →
CCRCC	DFS	Tertile	All	0.951	0.863	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTHFR–HNSC (OS)

Open the HNSC breakdown →